Analytical validation of fecal 3-bromotyrosine concentrations in healthy dogs and dogs with chronic enteropathy

Sattasathuchana, Panpicha; Thengchaisri, Naris; Suchodolski, Jan S.; Lidbury, Jonathan A.; Steiner, Jörg M.

doi:10.1177/1040638719831340

Cited by 4 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the focus of this analysis is on feces, as reports have evidenced that the assessment of 3-BrY concentrations in fecal samples reflect the level of eosinophil activation in the GI tract more accurately than serum biomarkers (Sattasathuchana et al, 2019). A recent study revealed higher concentrations of fecal 3-BrY concentrations in dogs with CIE; however, sensitivity and specificity to differentiate between the different forms of CIE are yet to be determined (Sattasathuchana et al, 2019). Sattasathuchana et al (2015Sattasathuchana et al ( , 2017 assessed 3-BrY concentrations in the serum of dogs with CIE.…”

Section: Fecal and Urinary Biomarkersmentioning

confidence: 99%

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

Sacoor¹,

Barros²,

Montezinho³

2021

Open Vet J.

View full text Add to dashboard Cite

Chronic inflammatory enteropathies in dogs are characterized by persistent or recurrent gastrointestinal signs that lastfor more than 3 weeks. Despite unclear etiopathogenesis, it is considered that a genetic predisposition associated withenvironmental factors, such as dietary antigens and intestinal microbiota, might induce an abnormal immune responsein the host. The diagnosis of this condition requires full investigation in order to exclude all other possible causes. Currently, the observation of clinical signs associated with histopathologic evaluation and systematic therapeutic trials is the gold standard for the diagnosis of chronic enteropathies. Furthermore, diagnosis, monitoring the disease progression, and treatment response evaluation can be exhausting, since this whole process is time-consuming, costly, and partially invasive. Therefore, biomarkers appear as non-invasive tools, which can be useful in evaluating gastrointestinal function, identifying the presence of the disease and assessing its natural progression, monitoring gastrointestinal inflammation, predicting response to treatment, and clinical outcomes. Over the past decade, several studies were conducted in order to explore the clinical utility of biomarkers. Thus, the aim of this dissertation is to provide an overview of the biomarkers considered relevant in the diagnosis and management of dogs with chronic inflammatory enteropathies. The biomarkers addressed in this study may be serological, present in urine and feces, or even tissue-derived. This study argues that biomarkers, in particular calprotectin and calgranulin C, have great potential to be used in clinical practice in the diagnosis and management of affected dogs. However, a single biomarker cannot assuredly predict disease severity, progression, response to treatment, and clinical outcomes. Therefore, in order to achieve greater accuracy, it would be beneficial if these tools are used in conjunction with contemporary ones. Future research is needed with the aim to better determine the usefulness of these tools in chronic inflammatory enteropathies in dogs.

show abstract

Section: Fecal and Urinary Biomarkersmentioning

confidence: 99%

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

Sacoor¹,

Barros²,

Montezinho³

2021

Open Vet J.

View full text Add to dashboard Cite

show abstract

“…The concentrations of 3-BrY in serum and fecal samples were measured using stable isotope dilution and electron ionization gas chromatography/mass spectrometry, with synthetic deuterated-BrY (D3-bromotyrosine) as the internal standard, as previously described [11,12,19]. A reference interval for canine serum 3-BrY concentration was previously established as ≤0.6 µmol/L based on samples from 41 healthy dogs [11,12,19].…”

Section: Measurement Of Serum and Fecal 3-bry Concentrationsmentioning

confidence: 99%

“…Lymphocytic-plasmacytic gastroenteritis and eosinophilic gastroenteritis are the two most common histological findings in dogs with CIE, whereas other inflammatory cell types such as neutrophils, monocytes, and macrophages are less frequently identified [2,3,6]. Multiple biomarkers for CIE have been developed and evaluated for assessing organ function, disease activity and severity, and disease outcome [1,3,[7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

“…This stable product is produced when the highly reactive oxygen species hypobromous acid (HOBr) reacts with tyrosine under physiological conditions [16][17][18]. A method for the measurement of the 3-BrY concentration in biological samples from dogs using electron impact gas chromatography-mass spectrometry (EI-GC/MS) has been established and analytically validated [12,19]. Previous studies have demonstrated that both serum and fecal 3-BrY concentrations were higher in dogs with CIE compared to clinically healthy dogs [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

“…A method for the measurement of the 3-BrY concentration in biological samples from dogs using electron impact gas chromatography-mass spectrometry (EI-GC/MS) has been established and analytically validated [12,19]. Previous studies have demonstrated that both serum and fecal 3-BrY concentrations were higher in dogs with CIE compared to clinically healthy dogs [10][11][12]. The clinical usefulness of the measurement of serum 3-BrY has been assessed in subtypes of dogs with CIE according to the response to treatment trials [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum and Fecal 3-Bromotyrosine Concentrations in Dogs with Chronic Inflammatory Enteropathy: Clinical Parameters and Histopathological Changes

Sattasathuchana,

Thengchaisri,

Minamoto

et al. 2023

Animals

Self Cite

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIEs) in dogs involve the infiltration of gastrointestinal tissue with inflammatory cells. This study aimed to assess the sensitivity of serum and fecal 3-bromotyrosine (3-BrY) concentrations in dogs with CIE. The difference in 3-BrY concentrations in dogs with different gastrointestinal (GI) pathological changes was also assessed. In total, 68 dogs with CIE were enrolled in the study. The median serum 3-BrY concentration was 3.3 µmol/L, while the median 3-day mean and maximum fecal 3-BrY concentrations were 38.9 and 63.2 mmol/g of feces, respectively. The median serum C-reactive protein concentration was 45.0 mg/L. The median 3-day mean and maximum fecal α1-proteinase inhibitor concentrations were 6.1 and 9 µg/g of feces, respectively. Increased 3-BrY concentrations were observed in 90.9% of CIE dogs based on serum concentrations, 75.8% based on mean fecal concentrations, and 69.4% based on maximum fecal concentrations. A weak correlation (ρ = 0.31, p < 0.0118) was found between serum CRP and serum 3-BrY concentrations. There was no correlation between the canine chronic enteropathy clinical activity index and serum or fecal 3-BrY concentrations (p > 0.05). Additionally, no significant difference in serum or fecal 3-BrY concentrations was found among CIE dogs with different GI pathological changes (p > 0.05). In conclusion, dogs with CIE have increased 3-BrY concentrations in serum and fecal samples. However, 3-BrY concentrations may not accurately indicate the severity of gastrointestinal inflammation.

show abstract

From Bench Top to Clinics

Hernandez

Dandrieux

2021

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Analytical validation of fecal 3-bromotyrosine concentrations in healthy dogs and dogs with chronic enteropathy

Cited by 4 publications

References 26 publications

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

Serum and Fecal 3-Bromotyrosine Concentrations in Dogs with Chronic Inflammatory Enteropathy: Clinical Parameters and Histopathological Changes

From Bench Top to Clinics

Contact Info

Product

Resources

About